Urinary tract infections: proven potentials of plant pharmacotherapy

Cover Page

Cite item

Full Text

Abstract

Urinary tract infection (UTI) is one of the most frequent infectious disorders. In modern protocols of acute uncomplicated UTI treatment antibiotics use is recommended as a first-line therapy. Although its frequent and unreasonable use may result in increase of antibiotic resistance development risk and microbiome alteration that leads to necessity of new approaches for UTI treatment development. Herbal based medications are a potential alternative for antibiotic use in acute uncomplicated UTI treatment. To compare the efficacy of herbal drug Canephron® H (BNO 1045) and fosfomycin trometamol (FT) for treatment of acute uncomplicated lower urinary tract infections (uLUTI) was carried out a multicentre double-blind controlled randomized trial in parallel groups (registration number NCT02639520), the results of which were presented in the article of principal investigator: F. Wagenlehner et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int 2018; 101 (3): 327-36. DOI: 10.1159/000493368. Epub 2018 Sep 19. Aim. Тo prove non-inferiority of herbal medication Canephron® N (BNO 1045) use in comparison with FT in acute uLUTI treatment. Materials and methods. Women aged 18-70 years with newly diagnosed acute uLUTI with typical symptoms were randomized for BNO 1045 (n=325) or FT (n=334) or placebo use. Results. In between Day 1 and Day 38 238 (83.5%) patients in BNO 1045 group and 272 (89.8%) patients in FT group did not use additional antibiotics. With the equivalence limit 15%, BNO 1045 demonstrated non-inferior effectiveness compared with FT in uLUTI treatment. The incidence of adverse events was equal in both groups, although in FT group incidence of gastrointestinal disorders was higher, and in BNO 1045 group - pyelonephritis incidence was higher. Conclusions. BNO 1045 has a potential to decrease antibiotics use in uLUTI treatment and its use, consequently, can result in significant changes in the strategy of antibacterial drugs rational use.

About the authors

- -

References

  1. Wagenlehner F.M, Weidner W, Naber K.G. An update on uncomplicated urinary tract infections in women. Curr Opin Urol 2009; 19: 368-74.
  2. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010; 7: 653-60.
  3. Loew D, Dieter D, Habs M et al. Erkrankungen der ableitenden Harnwege; in Loew D, Habs M, Klimm H-D, Trunzler G (eds): Phytopharmaka-Report: Rationale Therapie mit pflanzlichen Arzneimitteln. Heidelberg, Steinkopff-Verlag Heidelberg, 2013.
  4. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1. www.http: //uroweb.org/ guideline/urological-infections/
  5. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med 2016; 8: 39.
  6. Ventola C.L. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther 2015; 40: 277-83.
  7. Tandogdu Z, Cek M, Wagenlehner F et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol 2014; 32: 791-801.
  8. Bleidorn J, Hummers-Pradier E, Schmiemann G et al. Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: follow-up of a randomised controlled trial. Ger Med Sci 2016; 14: Doc01.
  9. Gagyor I, Bleidorn J, Kochen M.M et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015; 351: h6544.
  10. Kronenberg A, Butikofer L, Odutayo A et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 2017; 359: j4784.
  11. Stange R, Schneider B, Albrecht U et al. Results of a randomized, prospective, double-dummy, double-blind trial to compare efficacy and safety of a herbal combination containing Tropaeoli majoris herba and Armoraciae rusticanae radix with co-trimoxazole in patients with acute and uncomplicated cystitis. Res Rep Urol 2017; 9: 43-50.
  12. Künstle G, Brenneis C, Haunschild J. Efficacy of Canephron® N against bacterial adhesion, inflammation and bladder hyperactivity. Eur Urol (Suppl.) 2013; 12: e671.
  13. Künstle G, Brenneis C, Pergola C et al. Anti-inflammatory effects of Canephron® N and effectiveness in a model of interstitial cystitis. Urologe 2013; 52 (Suppl. 1): e97.
  14. Brenneis C, Künstle G, Haunschild J. Spasmolytic Activity of CanephronR N on the Contractility of Rate and Human Isolated Urinary Bladder: 13th International Congress of the Society for Ethnopharmacology. 2nd to 6th September 2012, Graz, Austria.
  15. Nausch B, Koeberle A, Werz O et al. 262 CanephronR N reduces pain in experimental cystitis and prostatitis putatively by inhibition of PGE2 production. Eur Urol (Suppl.) 2016; 15: e262.
  16. Haloui M, Louedec L, Michel J.B, Lyoussi B. Experimental diuretic effects of Rosmarinus officinalis and Centaurium erythraea. J Ethnopharmacol 2000; 71: 465-72.
  17. Naber K.G, Kogan M, Wagenlehner FME et al. How the microbiome is influenced by the therapy of urological diseases: standard versus alternative approaches. Clinical Phytoscience 2017; 3: 8.
  18. Wullt B, Svanborg C. Deliberate establishment of asymptomatic bacteriuria - a novel strategy to prevent recurrent UTI. Pathogens 2016; 5: 52.
  19. Naber K, Steindl H, Abramov-Sommariva D, Eskoetter H. Non-antibiotic herbal therapy of uncomplicated lower urinary tract infection in women - a pilot study. Planta Med 2013; 79: PB1.
  20. Alidjanov J.F, Abduffattaev U.A, Makhsudov S.A et al. New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: acute cystitis symptom score. Urol Int 2013; 92: 230-6.
  21. Alidjanov J.F, Abdufattaev U.A, Makhsudov S.A et al. The acute cystitis symptom score for patient-reported outcome assessment. Urol Int 2016; 97: 402-9.
  22. Kranz J, Schmidt S, Lebert C et al. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention. Urol Int 2018; 100: 263-70.
  23. Christiaens T.C, De Meyere M, Verschraegen G et al. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002; 52: 729734.
  24. Ferry S.A, Holm S.E, Stenlund H et al. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis 2004; 36: 296-301.
  25. Stamm W.E, Counts G.W, Running K.R et al. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med 1982; 307: 463-8.
  26. Hooton T.M, Roberts P.L, Cox M.E, Stapleton A.E. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med 2013; 369: 1883-91.
  27. Ferry S.A, Holm S.E, Stenlund H et al. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. Scand J Prim Health Care 2007; 25: 49-57.
  28. LaRocco M.T, Franek J, Leibach E.K et al. Effectiveness of preanalytic practices on contamination and diagnostic accuracy of urine cultures: a laboratory medicine best practices systematic review and meta-analysis. Clin Microbiol Rev 2016; 29: 105-47.
  29. Набер К.Г., Коган М.И., Вагенленер Ф. и др. Как терапия урологических заболеваний влияет на микробиом: стандартные подходы в сравнении с альтернативными. Clin Phytosci 2017; 3 (8). DOI. org/10.1186/s40816-017-0045-8 @@Naber K.G., Kogan M.I., Vagenlener F. et al. Kak terapiia urologicheskikh zabolevanii vliiaet na mikrobiom: standartnye podkhody v sravnenii s al'ternativnymi. Clin Phytosci 2017; 3 (8). DOI. org/10.1186/s40816-017-0045-8 (in Russian)
  30. EAU Guidelines on Urological Infections 2015 EAU website: http: //www.uroweb.org/guidelines/online-guidelines/
  31. Wagenlehner F.M, Bartoletti R, Cek M et al. Antibiotic stewardship: a call for action by the urologic community. Eur Urol 013; 64: 358-60.
  32. Guarner F, Malagelada J-R. Gut flora in health and disease. Lancet 2003; 361: 512-9. doi: 10.1016/S0140-6736 (03) 12489-0
  33. Захарова И.Н., Османов И.М., Касьянова А.Н. и др. Протективные факторы слизистой оболочки мочевого пузыря - ключ к новым подходам к терапии инфекции мочевых путей. Рос. вестн. перинатол. и педиатр. 2018; 63 (2): 16-21. doi: 10.21508/1027-4065-2018-63-2-16-21 @@Zakharova I.N., Osmanov I.M., Kas'ianova A.N. et al. Protektivnye faktory slizistoi obolochki mochevogo puzyria - kliuch k novym podkhodam k terapii infektsii mochevykh putei. Ros. vestn. perinatol. i pediatr. 2018; 63 (2): 16-21. doi: 10.21508/1027-4065-2018-63-2-16-21 (in Russian)

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies